Novartis, a world leader in pharmaceuticals and consumer health, is in talks with UAE officials to strengthen co-operation on medical research and educational projects.Professor Paul Herrling, head of corporate research at Novartis International, arrived in Dubai for discussions with government and medical organisations about the potential for collaboration on new initiatives.In his discussions with local health authorities, Prof Herrling focused on thalassaemia - a genetic blood disorder which has a particularly high incidence within the UAE and wider Middle East. Novartis is a pioneer in the treatment of this condition through its key medication Desferal, including upcoming new oral medications.These factors increase the importance of ongoing research and educational initiatives.
